Know Cancer

forgot password

A Phase II, Open-Label Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-β

Phase 2
18 Years
Not Enrolling
Bladder Cancer

Thank you

Trial Information

A Phase II, Open-Label Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-β

CDX-1307 is an experimental vaccine that is designed to generate an immune response against
a protein called human chorionic gonadotropin-beta (hCG-β). hCG-β is made by several types
of cancers, including bladder cancer, and has been shown to be associated with shorter times
to development of metastases and reduced survival in bladder cancer. In this study, it is
hoped that administering the CDX-1307 vaccine will cause the body's immune system to attack
bladder cancer cells in order to kill them or otherwise keep them from spreading or coming

Standard treatment for early stage, muscle invasive bladder cancer includes the
administration of chemotherapy to shrink the tumor followed by surgical removal of the
bladder (cystectomy).

This study will compare the effect of adding CDX-1307 administration to this standard
treatment. CDX-1307 will be given with 3 different immune stimulants to try to increase the
immune response against the tumor cells; collectively, this is called the "CDX-1307 vaccine

Only patients whose tumors make the hCG-β protein will be included in this study. Eligible
patients will receive "standard of care" chemotherapy with the CDX-1307 vaccine regimen
before surgery, and then CDX-1307 vaccine regimen alone (without chemotherapy) after

Inclusion Criteria:

Among other criteria, patients must meet all of the following conditions to be eligible to
be in the study:

1. 18 years of age or older.

2. Newly diagnosed muscle-invasive transitional cell (urothelial) bladder cancer where
neoadjuvant chemotherapy and radical cystectomy with curative intent are indicated
(i.e., American Joint Committee on Cancer (AJCC) stage T2-4a, Nany, M0). Patients
must be entered into the study within eight weeks of their most recent diagnostic
procedure, which is usually a diagnostic biopsy or transurethral resection of bladder
tumor (TURBT) procedure.

3. Histopathologically confirmed, transitional cell (urothelial) carcinoma. Urothelial
tumors with mixed histology (but with <50% variant) are eligible.

4. Tumor tissue (obtained during a prior procedure) confirmed to express hCG-β by a
central laboratory.

5. Candidate for therapy with neoadjuvant chemotherapy.

Exclusion Criteria:

Among other criteria, patients who meet any of the following conditions are NOT eligible
to be in the study:

1. Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior
immunotherapy or intravesical (administered within the bladder) chemotherapy for
superficial disease is acceptable.

2. History of anaphylactic reaction following exposure to humanized or human therapeutic
monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products,
clinically meaningful allergic reactions to imiquimod, resiquimod, or any known
hypersensitivity or prior reaction to any of the formulation excipients in the study

3. Concurrent chronic treatment with immunosuppressive or immunomodulatory agents,
including any systemic steroid (exception: inhaled or topically applied steroids, and
acute and chronic standard dose NSAIDs, are permitted).

4. Known infection with HIV, HBV or HCV.

5. Any underlying medical condition that, in the Investigator's opinion, will make the
administration of study vaccine hazardous to the patient, would obscure the
interpretation of adverse events, or would contraindicate receipt of neoadjuvant
chemotherapy or surgical resection.

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

2 year Recurrence-Free Survival Rate

Outcome Description:

The 2-year recurrence-free survival rate will be estimated based on the proportion of patients who are classified as alive and without documented disease recurrence at this time point.

Outcome Time Frame:

2 years following enrollment

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

April 2010

Completion Date:

October 2017

Related Keywords:

  • Bladder Cancer
  • bladder cancer
  • immunotherapy
  • cystectomy
  • cancer vaccine
  • human chorionic gonadotropin
  • hCG
  • urogenital neoplasms
  • urinary bladder neoplasms
  • muscle invasive
  • non-metastatic
  • transitional cell (urothelial) bladder cancer
  • Urinary Bladder Neoplasms



University of Colorado Cancer Center Denver, Colorado  80262
University of Iowa Hospitals and Clinics Iowa City, Iowa  52242
Washington University School of Medicine Saint Louis, Missouri  63110
SUNY Upstate Medical University Syracuse, New York  13210
University of Florida Gainesville, Florida  32610-0277
University of Rochester Rochester, New York  14642
Henry Ford Health System Detroit, Michigan  48202
Thomas Jefferson University Philadelphia, Pennsylvania  19107-6541
Roswell Park Cancer Center Buffalo, New York  14263
Moffitt Cancer Center Tampa, Florida  33612
University of Maryland Greenebaum Cancer Center Baltimore, Maryland  21201
Syracuse VA Medical Center Syracuse, New York  13210
Weill Cornell Medical College New York, New York  10021
BCG Oncology, PC Phoenix, Arizona  85032
University of California - San Diego La Jolla, California  92093
University of Southern California Norris Comprehensive Cancer Center LA-USC Medical Center Los Angeles, California  90033
University of Kentucky Markey Cancer Center Clinical Research Organization Lexington, Kentucky  40536-0093